Goldman Sachs analysts added UCB (UCBJF) to the firm’s European Conviction List as part of its monthly update. The firm believes UCB offers a “rare opportunity” within European biopharma to own a blockbuster launch.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UCBJF: